Sclerostin linked to vascular disease in type 2 diabetes


Circulating levels of the Wnt/β-catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in Diabetes Care.

Read more

Posted in Medical Research Type II